Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Milagros Domecq"'
Autor:
Oneyda Clapé-Laffita, María V. Perrand-Roberts, Milagros Domecq-Salmon, Maryenis Rodríguez-Alfaro, Maritza Cebreco-Sardina
Publikováno v:
Journal of Pharmacy & Pharmacognosy Research, Vol 9, Iss 3, Pp 324-332 (2021)
Context: Immunotherapy, by directing the immune response against tumor cells, complements the oncological therapy along with conventional treatments. Thus, the monoclonal antibody nimotuzumab blocks the binding of epidermal growth factor to its recep
Externí odkaz:
https://doaj.org/article/ce3908cd1824483da61b68c9fcaf0ddf
Autor:
Ana de la Torre, Kirenia Pérez, Aliz M. Vega, Eduardo Santiesteban, Raiza Ruiz, Leonardo Hernández, Dayamí Durrutí, Carmen E. Viada, Liset Sánchez, Mabel Álvarez, Yunier Durán, Yoisbel G. Moreno, Maylén Arencibia, Meylán Cepeda, Milagros Domecq, Leticia Cabrera, Jorge L. Sánchez, José J. Hernández, Ana R. Valls, Luis E. Fernández
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2016, Iss 10, Pp 5-11 (2016)
Externí odkaz:
https://doaj.org/article/5c7ae05b0fd04052879410a20001971c
Autor:
Oneyda Clapé-Laffita, María V. Perrand-Roberts, Milagros Domecq-Salmon, Maryenis Rodríguez-Alfaro, Maritza Cebreco-Sardina
Publikováno v:
Journal of Pharmacy & Pharmacognosy Research. 9:324-332
Context: Immunotherapy, by directing the immune response against tumor cells, complements the oncological therapy along with conventional treatments. Thus, the monoclonal antibody nimotuzumab blocks the binding of epidermal growth factor to its recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c25dc895d63fec5333de36ae353189d4
https://doi.org/10.56499/jppres20.958_9.3.324
https://doi.org/10.56499/jppres20.958_9.3.324
Autor:
Alejandro Martínez, Lázaro Manuel Filgueira, Ulises Castillo, Danay Saavedra, Elio Meriño, Mayra Ramos, C. Hidalgo, Alberto Ramírez, Geydi Lorenzo, Julio Betancourt, Carmen Valenzuela, Patricia Lorenzo, Yanelda García, Lilia M Ortega, Henrry Diaz, Meylan Cepeda, Maylén Arencibia, Milagros Domecq, Lizet Sánchez, Tania Crombet, Zaima Mazorra, Daymys Estevez, Alberto Escalona, Rolando E Despaigne, Kalet León, Naivy Sánchez, Leticia Cabrera, Armando Caballero
Publikováno v:
Clinical & Translational Immunology
Objectives COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9483cd7804b251be1212932961b9ee4e
https://doi.org/10.1002/cti2.1218
https://doi.org/10.1002/cti2.1218